In vivo and in vitro effect of FK 506 on rat leydig cell function by Tai, J et al.
-------_._-_. --_ .. _. 
In Vivo and In Vitro Effect of FK 506 on Rat Leydig Cell Function 
J. Tai, W.J. Tze, N. Murase, A. Tzakis, and T.E. Starzl 
FK 506 is a macrolide antibiotic with powerful immu-
nosuppressive activities. It is known to prevent al-
lograft rejection in rats, dogs, monkeys, baboons, and 
humans. 1.2 In vitro studies indicate that, like cyclosporine 
(Cy A), FK 506 acts specifically by inhibiting the transcrip-
tion of a limited set of early T-cell activation genes, 
including those encoding interleukin-2 (IL-2), IL-3, IL-4, 
and interferon-gamma (IFN-y).3 There are reports indicat-
ing that CyA impairs testicular steroidogenesis and sper-
matogenesis in rats.4 •5 The immunosuppressive effect of 
FK 506 is many times more potent than that of Cy A and to 
date there are no published studies concerning toxicity of 
FK 506 on testicular functions. The present study was 
undertaken to assess the in vivo and in vitro effects of FK 
506 on rat Leydig cell function. 
MATERIALS AND METHODS 
Anima.ls and FK 506 Treatment Protocol 
Adult male ACI rats (Harlan Sprague Dawley Inc, Indianapolis. 
Ind) weighing 225 to 300 g were used for all experiments. The 
animals were provided with rat chow and water ad libitum. An 
injectable form of FK 506 (Fujisawa Pharmaceutical Co) was 
prepared daily in saline and given 1M at I mglkgld or 2 mglkgld for 
14 consecutive days to ACI rats. The control animals received 
saline 1M. 
Assessment of Testicular Function In Vivo 
FK 506-treated and control rats were given a subcutaneous 
injection of human chorionic gonadotropin (hCO) (Sigma Chemi-
cal Co, St Louis, Mo; cat. COlO) at 300 IV/250 g body weight. 
Blood samples collected at 0,4,8, and 24 hours were measured for 
total testosterone levels by radioimmunoassay (TKTT2, Diagnos-
tic Products, CaliO.6 
Preparation of Dispersed Leydig Cells 
Dispersed cells from testes were prepared with a modification of 
the protocol of Simpson et al with 0.2 mglmL purified collagenase 
(Type XI, Sigma).? The purity of Leydig cells in the preparation 
was regularly over 85%, as determined by specific staining for 
3,B-HSD activity.s Cellular viability was >90% by trypan blue dye 
exclusion test. Cellular viability in each preparation was also 
determined during and at the end of in vitro incubation period in 
the presence of varying concentrations of FK 506. 
In Vitro Culture of Leydig Cells With FK 506 
Stock solution of pure FK S06 (I mglmL) (Lot 011050L, Fujisawa) 
was prepared in absolute ethanol and then diluted in DME 
nutrient mixture F-12 Ham medium supplemented with 20% 
newborn calf serum. O.S millionlmL Leydig cells were incubated 
in 10 x 7S-mm sterile polystyrene culture tubes in concentrations 
of FK S06 ranging from 10 to 10,000 ngimL. Leydig cells were 
incubated for between 15 to 17 hours in a S% CO2 incubator at 
34°C. At the end of the incubation period, the tubes were shaken 
to mix the medium and then centrifuged at 600g for 7 minutes at 
4°C. The supernatant was saved at -20°C for testosterone assay. 
The cells were then washed two times with culture medium 
followed by an additional 3 hours of incubation at 34°C. The 
culture media were saved for testosterone assay. 
Data were analyzed statistically by Student's t test with the 
level of significance set at P < .05. 
RESULTS 
Figure I shows the serum testosterone levels in response 
to hCG stimulation in normal ACI rats before, immediately 
after, and 4 weeks after a course of 14 daily 1M injections 
of FK 506 at I mg/kg/d. Though the basal testosterone 
levels in ACI rats treated with FK 506 were lower than that 
before the FK 506 treatment, the values were not signifi-
cantly different. The rats that received a course of FK 506 
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Fig 1. Effect of FK 506 on serum testosterone levels (mean ± 
SEM) in response to hCG stimulation (300 IU/250 g body weight 
subcutaneously) in ACI rats before (D), immediately after (_), and 
4 weeks after (!iJ:l) a course of 141M injections of FK 506 at 1 
mg/kg/d. Data represent combined results from two separate 
experiments (n = 12 to 18). * P < .05 compared with the control 
group. 
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Fig 2. Effect of FK 506 on serum testosterone levels (mean ± 
SEM) in response to hCG stimulation (300 IU/250 g body weight 
subcutaneously) in normal ACI rats (.; n = 4) and ACI rats treated 
with FK 506 at 2 mg/kg/d for 2 weeks E~; n = 8). * P < .05 
compared with the control group. 
injections showed good response to the hCG stimulation. 
However, the testosterone levels were significantly lower 
than the normal controls at 24 hours. The subnormal 
response was temporary as the testosterone response to 
hCG stimulation normalized when the animals were 
retested 4 weeks after the discontinuation of the FK 506 
treatment. 
Figure 2 shows that 2 weeks of 1M treatment with a high 
dose FK 506 at 2 mg/kg/d did not significantly affect the 
basal testosterone levels in normal ACI rats. In addition, 
the testosterone response to hCG stimulation at 8 and 24 
hours was not affected. However, the level at 4 hours was 
significantly higher than in controls. 
FK 506 was then tested in vitro on ACI Leydig cells a 
minimum of three times and since the results were com-
parable in these experiments only one of them is pre-
sented. Figure 3 shows the effect of short-term in vitro 
treatment of FK 506 in concentrations ranging from 10 to 
10,000 ng/mL on testosterone secretion from purified ACI 
rat Leydig cells. Overnight culture of Leydig cells in the 
presence of FK 506 up to 1,000 ng/mL did not inhibit the 
rate of their testosterone secretion. At 10,000 ng/mL, FK 
506 showed stimulatory effect on the secretion oftestoster-
one from these cells. The testosterone secretion rates after 
FK 506 removal were similar in the FK 506-treated cells 
and the controls except at 10,000 ng/mL samples of which 
showed significantly lower secretion rate. 
DISCUSSION 
FK 506 is a novel, potent immunosuppressive agent whose 
application in experimental and clinical organ transplanta-
tions has resulted in markedly improved graft survival. 1.2 
Its biologic action is considered to be similar to Cy A. Cy A 
has been shown to have a deleterious effect on the male 
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Fig 3. Effect of short-term in vitro treatment of FK 506 on 
testosterone secretion from ACI rat Leydig cells. The solid bars 
show the hourly rate of testosterone secretion (mean ± SEM; n = 
3) by Leydig cells during the 15 hours of culture in the presence of 
FK 506 at concentrations varying from 10 to 10,000 ng/mL. The 
hatched bars show the subsequent rate of testosterone release for 
an additional 3 hours after the removal of FK 506. * P < .05 
compared with the control group. 
reproductive function of rats4 ,5,9 but the effects of FK 506 
on steroidogenesis of Leydig cells is not known. The result 
of this study demonstrated that a regimen of 1M injections 
of FK 506 for 14 days at 1 or 2 mg/kg/d did not significantly 
alter the basal testosterone level and the testosterone 
response to hCG stimulation in young adult rats. These 
two FK 506 treatment regimens were chosen because they 
have been shown to be effective in the prolongation of 
allografts across major histocompatibility barrier. 10 
In vitro culture studies were performed to examine the 
effect of FK 506 on Leydig cell function without involving 
extragonadal influences that occur in the intact animal. 
The results indicate that short-term in vitro FK 506 treat-
ment at a dosage range equal or less than 1,000 ng/mL does 
not appear to have any direct inhibitory effect on testoster-
one biosynthesis in ACI rat Leydig cells. The Leydig cells 
cultured in the presence of FK 506 also appeared to be 
normal morphologically. The dosage of FK 506 used 
exceeded the plasma concentrations of FK 506 of =7 and 
100 ng/mL, respectively, following daily 1M administration 
of 1 or 10 mg/kg/d to rats.1\ Whether longer in vitro 
treatment with FK 506 will affect the steroidogenesis of 
Leydig cells remains unclear until the problem to maintain 
consistent testosterone secretion from Leydig cells for 
more than 3 days in vitro is resolved. 12 
In conclusion, short-term treatment of FK 506 at effec-
tive immunosuppressive dosages did not affect Leydig cell 
steroidogenesis in young adult ACI rats. Short-term in 
vitro culture of Leydig cells in FK 506 did not depress their 
testosterone secretion nor reduce their viability. Since 
most organ transplant recipients remain on immunosup-
3204 
pression for life, further investigation using FK 506 treat-
ment for longer duration will be necessary. 
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